KNSA
Kiniksa Pharmaceuticals
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: KNSA
- PE Ratio
The price-to-earnings ratio for Kiniksa Pharmaceuticals stock stands at 48.83 as of Jun 3, 2026. This is calculated based on the current EPS of $0.98 and the stock price of $47.85 per share. A decrease of 70% has been recorded in the P/E ratio compared to the average of 160.3 of the last 4 quarters.
KNSA PE ratio history
Over the last four years, the average PE ratio of Kiniksa Pharmaceuticals has been 91.32. The current 48.83 PE ratio is 47% below the historical average. In the past four years, KNSA's PE ratio was at its highest in the Jun 2025 quarter at 461.17, with a price of $27.67 and an EPS of $0.06. The Mar 2023 quarter recorded the bottom point at 3.82, with a price of $10.76 and an EPS of $2.82.
Kiniksa Pharmaceuticals PE ratio by year
Maximum annual increase: 1,446.74% in 2023
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 51.56 | N/A | $41.25 | $0.8 |
| 2024 | N/A | N/A | $19.78 | -$0.6 |
| 2023 | 87.7 | 1,446.74% | $17.54 | $0.2 |
| 2022 | 5.67 | N/A | $14.98 | $2.64 |
| 2021 | N/A | N/A | $11.77 | -$2.3 |
| 2020 | N/A | N/A | $17.67 | -$2.61 |
| 2019 | N/A | N/A | $11.06 | -$2.99 |
| 2018 | N/A | N/A | $28.09 | -$3.49 |
| 2017 | N/A | N/A | N/A | -$35.85 |
| 2016 | N/A | N/A | N/A | -$91.61 |
Kiniksa Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 49.13 | -4.71% | $48.15 | $0.98 |
| Dec 2025 | 51.56 | -34.93% | $41.25 | $0.8 |
| Sep 2025 | 79.24 | -82.82% | $38.83 | $0.49 |
| Jun 2025 | 461.17 | N/A | $27.67 | $0.06 |
| Mar 2025 | N/A | N/A | $22.21 | -$0.24 |
| Dec 2024 | N/A | N/A | $19.78 | -$0.6 |
| Sep 2024 | N/A | N/A | $24.99 | -$0.13 |
| Jun 2024 | N/A | N/A | $18.67 | -$0.15 |
| Mar 2024 | 164.42 | 87.48% | $19.73 | $0.12 |
| Dec 2023 | 87.7 | N/A | $17.54 | $0.2 |
| Sep 2023 | N/A | N/A | $17.37 | -$0.11 |
| Jun 2023 | 4.24 | 10.99% | $14.08 | $3.32 |
| Mar 2023 | 3.82 | -32.63% | $10.76 | $2.82 |
| Dec 2022 | 5.67 | -8.99% | $14.98 | $2.64 |
| Sep 2022 | 6.23 | N/A | $12.84 | $2.06 |
KNSA Price vs fair value
KNSA average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
Currently, KNSA's PE ratio is lower than the 3 and 5-year averages.
PE comparison
With a P/E of 48.83, KNSA stands above the Healthcare sector and the industry average. Compared to its Healthcare sector average of 23.02, Kiniksa Pharmaceuticals's P/E is 112% higher.
KNSA PE vs peers
KNSA's PE ratio is higher than its peer stocks OMER and ORMP.
| Stock name | PE ratio | Market cap |
|---|---|---|
| VIVS VivoSim Labs Inc. | 0.77 | $3.49M |
| ORMP Oramed Pharmaceuticals Inc | 1.44 | $156.34M |
| OMER Omeros Corp | 7.88 | $741.12M |
| KNSA Kiniksa Pharmaceuticals Ltd | 50.33 | $3.79B |
| OLMA Olema Pharmaceuticals Inc | N/A | $931.12M |
| ORIC Oric Pharmaceuticals Inc | N/A | $830.21M |
Frequently asked questions
What is Kiniksa Pharmaceuticals's PE ratio?
The price to earnings ratio for KNSA stock as of Jun 3, 2026, stands at 48.83.
What is the 3-year average PE ratio for Kiniksa Pharmaceuticals (KNSA)?
Over the last 3 years, the average price to earnings ratio for KNSA stock is 128.21.
What is the 5-year average PE ratio for Kiniksa Pharmaceuticals (KNSA)?
Over the last 5 years, the average price to earnings ratio for KNSA stock is 91.32.
What is the highest PE ratio for KNSA?
Over the last four years, the quarterly PE ratio reached a historic high of 461.17 in the Jun 2025 quarter.
How does the current PE ratio for KNSA compare to its historical average?
The current price to earnings ratio of KNSA is 47% lower than the 4-year historical average.
How is KNSA's PE ratio calculated (Kiniksa Pharmaceuticals PE ratio formula)?
To determine the PE ratio, divide the most recent stock price by the TTM earnings per share (EPS). As of today (Jun 3, 2026), Kiniksa Pharmaceuticals's stock price is $47.85. The earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $0.98. Therefore, Kiniksa Pharmaceuticals's P/E ratio for today is 48.83. PE RATIO(48.83) = STOCK PRICE($47.85) / TTM EPS($0.98)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.